← Back to Search

Chemotherapy

Phosphorus-32 + Radiotherapy + Chemotherapy for Lung Cancer

Phase 1

Waitlist Available

Research Sponsored by Center for Molecular Medicine

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Unresectable or inoperable disease OR Refusal of surgery

No clinical/radiographic evidence of metastatic disease

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 5 years

Awards & highlights

Study Summary

This trial is studying how well giving phosphorus-32, radiation therapy, and chemotherapy together works in treating patients with stage II or stage III non-small cell lung cancer.

Who is the study for?

This trial is for adults over 18 with stage II or III non-small cell lung cancer that can't be removed by surgery or patients who refuse surgery. They must have a tumor accessible for CT-guided needle placement, no distant metastases, stable weight, normal liver and kidney function, no other cancers in the past 5 years except skin cancer, not pregnant and using contraception if fertile.Check my eligibility

What is being tested?

The study is testing the combination of phosphorus-32 (a radioactive substance), radiation therapy, and chemotherapy to see how well it works against non-small cell lung cancer at stages II or III. The goal is to determine if this combo is more effective in killing tumor cells than current treatments.See study design

What are the potential side effects?

Potential side effects may include damage to healthy cells leading to symptoms like fatigue, nausea, hair loss from chemotherapy; skin irritation or injury to nearby organs from radiation; and specific risks associated with phosphorus-32 such as increased radiation exposure.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

My condition cannot be treated with surgery or I have chosen not to undergo surgery.

Select...

My cancer has not spread to other parts of my body as per tests.

Select...

My blood urea nitrogen is 25 mg/dL or less, and my creatinine is 1.5 mg/dL or less.

Select...

My disease can be measured on an X-ray or CT scan.

Select...

I am over 18 years old.

Select...

My lung cancer is at stage II, IIIA, or IIIB and has not been treated before.

Select...

I can care for myself but may not be able to do active work.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 5 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 5 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

0 / 7Eligibility criteria met

Find a Location

Who is running the clinical trial?

Center for Molecular MedicineLead Sponsor

5 Previous Clinical Trials

213 Total Patients Enrolled

Wayne S. Court, MD, PhDStudy ChairCenter for Molecular Medicine

1 Previous Clinical Trials

Media Library

Chemotherapy (Chemotherapy) Clinical Trial Eligibility Overview. Trial Name: NCT00006212 — Phase 1

Lung Cancer Clinical Trial 2023: Chemotherapy Highlights & Side Effects. Trial Name: NCT00006212 — Phase 1

Chemotherapy (Chemotherapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT00006212 — Phase 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are researchers still recruiting participants for this experiment?

"According to current data hosted on clinicaltrials.gov, this trial is not actively recruiting at the moment. Initially posted in November 1999 and most recently updated in September 2013, it appears that no additional participants are being sought for the time being. However, there are 1629 other experiments around the world presently accepting enrollees."

Answered by AI

Have regulatory bodies sanctioned this form of therapy?

"Our team at Power believes the safety of this treatment to be a 1 due to limited data in its support. This is a Phase 1 trial, which means efficacy and safety have been tested minimally."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Phosphorus-32 Plus Radiation Therapy and Chemotherapy in Treating Patients With Stage II or Stage III Non-small Cell Lung Cancer

1999. "Phosphorus-32 Plus Radiation Therapy and Chemotherapy in Treating Patients With Stage II or Stage III Non-small Cell Lung Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT00006212.

All > Lung > Sclc